Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Gross Margin (2021 - 2025)

Apellis Pharmaceuticals (APLS) has 5 years of Gross Margin data on record, last reported at 85.13% in Q4 2025.

  • For Q4 2025, Gross Margin rose 436.0% year-over-year to 85.13%; the TTM value through Dec 2025 reached 89.81%, up 488.0%, while the annual FY2025 figure was 89.81%, 488.0% up from the prior year.
  • Gross Margin reached 85.13% in Q4 2025 per APLS's latest filing, down from 94.65% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.92% in Q4 2021 and bottomed at 79.4% in Q1 2025.
  • Average Gross Margin over 5 years is 88.93%, with a median of 88.35% recorded in 2024.
  • Peak YoY movement for Gross Margin: plummeted -1404bps in 2023, then surged 1170bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 99.92% in 2021, then fell by -13bps to 87.09% in 2022, then dropped by -1bps to 86.4% in 2023, then decreased by -7bps to 80.78% in 2024, then increased by 5bps to 85.13% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 85.13% in Q4 2025, 94.65% in Q3 2025, and 92.37% in Q2 2025.